Skip to main
BMY

Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers (BMY) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 24%
Hold 41%
Sell 6%
Strong Sell 0%

Bulls say

Bristol-Myers Squibb is positioned for potential positive growth in the 2026 fiscal year, with a solid quarter expected for their Growth Products, a confident outlook for Eliquis sales, and promising upcoming clinical readouts. Their focus on developing drugs for key therapeutic areas and their ongoing efforts in mergers and acquisitions also bode well for their future success. These factors, combined with their projected financial data, make Bristol-Myers Squibb a favorable investment opportunity.

Bears say

Bristol-Myers Squibb is facing several downside risks, such as potential competition in the rare CV, I&I, and oncology space, clinical failure of their pipeline programs, regulatory delays, and macroeconomic or policy-related risks. While the company has made updates to their model, increasing their PoS for some of their drugs and updating revenue and EPS estimates, their dependence on the US market and potential competition may impact their future growth and profitability.

Bristol-Myers (BMY) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 24% recommend Buy, 41% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bristol-Myers (BMY) Forecast

Analysts have given Bristol-Myers (BMY) a Buy based on their latest research and market trends.

According to 17 analysts, Bristol-Myers (BMY) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65.06, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65.06, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bristol-Myers (BMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.